Treatment

Perjeta 420 mg concentrate for solution for infusion clinical trials

6 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
This study is looking at new ways to treat early-stage breast cancer before standard surgery. It's for people with specific types of breast cancer (triple-negative or HER2+). Researchers are testing if certain immune-boosting medicines can help the body fight the cancer better, hoping to improve treatment outcomes.
For: Newly diagnosed · non-metastatic early-stage triple-negative or HER2+ breast cancer
France
AuthorisedTherapeutic confirmatory (Phase III)
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
This study looks at new drug combinations for women with a certain type of aggressive breast cancer before surgery. It aims to see if these treatments can stop the cancer from coming back and improve long-term health, comparing their effects and safety.
For: Invasive Breast Cancer
Spain · Germany · Italy
AuthorisedPhase II and Phase III (Integrated)
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
This study is testing a new drug, TherO2-01S22, for people with metastatic breast cancer that is HER2-positive. It aims to see how well it works and if it's safe when added to standard treatments. Researchers want to understand if it can shrink tumours.
For: metastatic breast cancer
France
AuthorisedTherapeutic confirmatory (Phase III)
A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer
For: breast cancer
Sweden · Finland
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administrationin Participants with Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
For: Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
Spain · Bulgaria · Croatia
Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.
For: Patients with PIK3CA-mutant · HER2-positive locally advanced or metastatic breast cancer · candidates to receive maintenance therapy with trastuzumab plus pertuzumab (HP) after first line treatment for metastatic disease with a taxane or vinorelbine plus HP.
Spain

Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer

A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.